Vaxart Announces Publication Of Preclinical Study Results Evaluating Its Oral Mucosal Vaccine Platform Against Highly Pathogenic Avian Influenza H5N1; Candidate VXA-H5-02 Induced Robust Cross-Neutralizing Antibodies

Loading news article.

Vaxart Announces Publication Of Preclinical Study Results Evaluating Its Oral Mucosal Vaccine Platform Against Highly Pathogenic Avian Influenza H5N1; Candidate VXA-H5-02 Induced Robust Cross-Neutralizing Antibodies | WAPE

Vaxart Announces Publication Of Preclinical Study Results Evaluating Its Oral Mucosal Vaccine Platform Against Highly Pathogenic Avian Influenza H5N1; Candidate VXA-H5-02 Induced Robust Cross-Neutralizing Antibodies

Article summary

Related companies

Comments —